Synthetic peptides for the treatment of myasthenia gravis

Details Synthetic peptides for the treatment of myasthenia gravis Synthetic peptides for the treatment of myasthenia gravis

1995-06-07

2000-05-23

Chan, Christina Y.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 514 13, 514 14, 530324, 530325, 530326, 530329, 530328, 530403, A61K 3800

Patent

active

060666218

ABSTRACT:
Peptides having at least nine amino acid residues each including an amino acid sequence which corresponds to position p200-208 or p262-266 of the human acetylcholine receptor .alpha.-subunit, but differing therefrom by one or more amino acid substitutions, are disclosed. These peptides inhibit the proliferative response of human peripheral blood lymphocytes to the myasthenogenic peptides p195-212 and p259-271 and are suitable for treatment of subjects afflicted with myasthenia gravis.

REFERENCES:
patent: 5116944 (1992-05-01), Sivam et al.
Wraith et al., Cell, 59: 247-255, Oct. 1989.
Tisch et al., Proc. Natl. Acad. Sci. USA, 91: 437-438, Jan. 1994.
Urban et al. Cell vol. 59:257-271, 1989.
Brocke et al. J.C.I. vol. 82:1894-1900, 1988.
Janeway. Nature. vol. 341: 482-483, 1989.
Zisman et al, "Peptide analogs to pathogoenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis", Proc. Natl. Acad. Sci. USA, 93:4492-4497 Apr. 1996.
Roit, I.M. Essential Immunology, 5th Edition, Blackwell Scientific Publications, Oxoford, UK, 1984, pp. 65-66.
Rothbard, J.B. et al., International Immunology, l1, 479-486, 1989.
Mozes, E. et al., EMBO Journal, 8, 4049-4052 (1989).
Smilek, D.E. et al., Immunol. Rev., 118, 37-71 (1990).
Busch, R. et al., International Immunology, 2, 444-451 (1990).
Chemical Abstracts, vol. 112, No. 19, May 1990, p. 537, abstr. No. 176542y, Columbus, OH; E. Mozes et al, "Direct binding of a myasthenia gravis related epitope to MHC class II molecules on murine antigen-presenting cells," & EMBO. J. 1989, 8(13), 4049-2.
Ceppellini, R. et al., "Binding of labelled influenza matric peptide to HLA DR in living B1 Lymphoid cells", Nature, vol. 339, Jun. 1989, pp. 392-394.
Budmer et al., Immunology, 66(2):163-169, 1989.
Sakai, K. et al., "Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins", Proc. Natl. Acad. Sci. USA, vol. 86, pp. 9470-9474, (1989).
Urban, James et al., "Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide-Based Therapy", Cell, vol. 59, Oct. 20, 1989, pp. 257-271.
Lindstrom, et al., Advances in Immunology, 42:233-284, 1988.
Lopez et al., J. Exp. Med, 170(1): 203-215, 1989.
Pola et al., J. Immunology, 141(7): 2289-2294, 1988.
Wraith et al., "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Meidated Immunotherapy", Cell, 59, pp. 247-255 (1989).
Wraith et al., "T cell recognition as the target for Immune Intervention in Autoimmune Diseases", Cell, 557, pp. 709-715, (1989).
Brocke et al., "In Vitro Proliferative Responses and Antibody Titers Specific to Human Acetylcholine Receptor Synthetic Peptides in Patients with Myasthenia Gravis and Relation to HLA Class II Genes", J. Clin. Invest., 82:1894-1900 (1988).
Madden et al., "The structure of HLA-B27 reveals nomamer self-peptides bound in an extended conformation", Nature, 353:321-325 (1991).
Katz-Levey et al., "Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs", Proc. Natl. Acad. Sci., 90:7000-7004 (Aug. 1993).
Brocke et al., "Inhibition of T cell proliferation specific for acetylcholine receptor epitopes related to myasthenia gravis with antibody to T cell receptor or with competitive syntheitc polymers", International Immunology, 2, #8, pp. 735-742(1990).
Plattner et al., "Obstacles to drug developement from peptide leads", pp. 92-126 in Drug Discovery Techniques, Clark et al., editor, Ellis Harwood Ltd. (1990).
Kirshner et al., "Altered Peptide Ligands of a Myasthenogenic Epitope as Modulators of Specific T-Cell Responses", Scand. J. Immunol., 44:512-521, 1996.
Zisman et al., "Binding of Peptides of the Human Acetylcholine Receptor .alpha.-Subunit to HLA Class II of Patients with Myastenia Gravis", Human Immunology, 44:121-130 (1995).
Kirshner et al., "Fine Specificity of T Cell Lines and Clones That Are Capable of Inducing Autoimmune Manifestations in Mice", Cellular Immunology, 157:11-28 (1994).
Brocke et al., "The autoimmune response of different mouse strains to T-cell epitopes of the human acetylcholine receptor .alpha. subunit", Immunology, 69:495-500, 1990.

Affiliated with

Also associated with

Rating

Synthetic peptides for the treatment of myasthenia gravis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic peptides for the treatment of myasthenia gravis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptides for the treatment of myasthenia gravis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1837155